SRRK
Scholar Rock Holding Corp Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$43.90Close
$4.8BMarket cap
$27.99 – $60.0452-week range
Nov 10, 2026Next report · before the open
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Far from its high 27% below its 52-week high
- Results soon Nov 10, 2026, in 9 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
27%
1wk
up 5.8%
price change
1mo
down 9.1%
price change
12-month return
up 49%
market up 11% ·
its own up 39%
F-score
—
— Not assessed
Altman Z
11.33
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
19.4×
price / book
Earnings yield
down 8.5%
EBIT / enterprise value
Cheaper than
9%
of the market · expensive
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 123%
return on equity
Free cash margin
—
-$300.6M FCF
D/E
0.41
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
4.3%
$1.90 a day · 2×ATR $40.11
RS
57 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
0.4×
vs 50-day average
Up/down volume
0.74
50 sessions
Implied move
—
no option chain · report Nov 10, 2026
Contractions
2
26% → 25%
Pivot
$51.74
15.1% below
Volume dry-up
0.9×
10 vs 50 sessions
Trend template · 2 of 8
- 150-day average above the 200-day: passes
- At least 30% above the 52-week low: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 15.6% over the year, from 94m to 108m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+10% vs market2 sessions after results
Financials
- Net
- Free cash
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $15.4M | $18.8M | $33.2M | — | — | $0 |
| Operating income | -$86.9M | -$129.9M | -$134.4M | -$171.3M | -$252.1M | -$384.6M |
| Net income | -$86.5M | -$131.8M | -$134.5M | -$166.0M | -$246.0M | -$378.0M |
| Net margin | -561% | -700% | -405% | — | — | — |
| Earnings per share | -$2.81 | -$3.59 | -$2.26 | -$1.99 | -$2.46 | -$3.30 |
| Free cash flow | -$64.4M | -$132.0M | -$133.8M | -$145.3M | -$201.0M | -$300.6M |
| Free cash margin | -418% | -702% | -403% | — | — | — |
| Cash | $160.4M | $212.8M | $103.3M | $101.9M | $177.9M | $323.5M |
| Long-term debt | $24.7M | $48.4M | $49.7M | $48.7M | $50.1M | $99.7M |
| Shareholders' equity | $260.8M | $172.1M | $260.2M | $225.2M | $368.6M | $245.5M |
| Shares outstanding | 34.15m | 35.21m | 51.67m | 75.98m | 93.82m | 108.46m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 3, 2026 | Annual ↗ | Dec 31, 2025 | 62d |
| Nov 14, 2025 | Quarterly ↗ | Sep 30, 2025 | 45d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Mar 19, 2024 | Annual ↗ | Dec 31, 2023 | 79d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 15, 2026 | Regulation FD ↗ |
| Sep 14, 2026 | Regulation FD · Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| Aug 6, 2026 | Other events ↗ |
| Jun 5, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results · Regulation FD ↗ |
| Mar 31, 2026 | Regulation FD · Other events ↗ |
| Mar 3, 2026 | Results · Regulation FD ↗ |
| Jan 12, 2026 | Results · Regulation FD · Other events ↗ |
| Dec 2, 2025 | Other events ↗ |
| Nov 14, 2025 | Other events ↗ |
| Nov 14, 2025 | Results · Regulation FD ↗ |